Prediction and management of cardiovascular outcomes in systemic lupus erythematosus

被引:10
作者
Frostegard, Johan [1 ]
机构
[1] Karolinska Inst, Unit Immunol & chron Dis, IMM, S-17175 Stockholm, Sweden
关键词
antibodies; atherosclerosis; cardiovascular disease; inflammation; risk factors; systemic lupus erythematosus; CORONARY-HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; VULNERABLE CAROTID PLAQUES; RISK-FACTORS; ATHEROSCLEROTIC PLAQUES; RHEUMATOID-ARTHRITIS; DENDRITIC CELLS; ACCELERATED ATHEROSCLEROSIS; AGGRAVATES ATHEROSCLEROSIS; MYOCARDIAL-INFARCTION;
D O I
10.1586/1744666X.2015.993970
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Atherosclerosis is the major cause of cardiovascular disease (CVD), which represents the major cause of death. During recent years, it has become clear that atherosclerosis is a chronic inflammatory condition where immunity could play an important role. Usually, it is when atherosclerotic plaques rupture that CVD follows, but some cases of CVD can occur without apparent atherosclerosis. In systemic lupus erythematosus, the risk of CVD is very high and the prevalence of atherosclerotic plaques, including vulnerable ones, is increased. A combination of traditional and non-traditional risk factors is implicated for the prediction of CVD in systemic lupus erythematosus. Traditional risk factors include hypertension, dyslipidemia, smoking and diabetes, though the exact importance of each of these in systemic lupus erythematosus is not clear. Anti-phospholipid antibodies, systemic inflammation and low levels of natural antibodies such as those against phosphorylcholine (anti-PC) are examples of non-traditional risk factors. Control of disease activity and disease manifestations and of established risk factors is important.
引用
收藏
页码:247 / 253
页数:7
相关论文
共 76 条
  • [21] Atherosclerosis in patients with autoimmune disorders
    Frostegård, J
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (09) : 1776 - 1785
  • [22] Antibodies to endothelial cells in borderline hypertension
    Frostegård, J
    Wu, RH
    Gillis-Haegerstrand, C
    Lemne, C
    de Faire, U
    [J]. CIRCULATION, 1998, 98 (11) : 1092 - 1098
  • [23] Immunity, atherosclerosis and cardiovascular disease
    Frostegard, Johan
    [J]. BMC MEDICINE, 2013, 11
  • [24] Low level natural antibodies against phosphorylcholine: A novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease
    Frostegard, Johan
    [J]. CLINICAL IMMUNOLOGY, 2010, 134 (01) : 47 - 54
  • [25] George J, 2000, CIRCULATION, V102, P1822
  • [26] Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases
    Ghittoni, Raffaella
    Napolitani, Giorgio
    Benati, Daniela
    Uliveri, Cristina
    Patrussi, Laura
    Pasini, Franco Laghi
    Lanzavecchia, Antonio
    Baldari, Cosima T.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2006, 36 (11) : 2885 - 2893
  • [27] Hafström I, 2007, J RHEUMATOL, V34, P1810
  • [28] Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study
    Haque, Sahena
    Gordon, Caroline
    Isenberg, David
    Rahman, Anisur
    Lanyon, Peter
    Bell, Aubrey
    Emery, Paul
    McHugh, Neil
    Teh, Lee Suan
    Scott, David G. I.
    Akil, Mohamed
    Naz, Sophia
    Andrews, Jacqueline
    Griffiths, Bridget
    Harris, Helen
    Youssef, Hazem
    McLaren, John
    Toescu, Veronica
    Devakumar, Vinodh
    Teir, Jamal
    Bruce, Ian N.
    [J]. JOURNAL OF RHEUMATOLOGY, 2010, 37 (02) : 322 - 329
  • [29] Premature coronary heart disease in SLE: can we prevent progression?
    Iaccarino, L.
    Bettio, S.
    Zen, M.
    Nalotto, L.
    Gatto, M.
    Ramonda, R.
    Punzi, L.
    Doria, A.
    [J]. LUPUS, 2013, 22 (12) : 1232 - 1242
  • [30] Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis
    Kang, S
    Wu, YF
    Li, X
    [J]. ATHEROSCLEROSIS, 2004, 177 (02) : 433 - 442